Stock RDHL REDHILL BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News RedHill Biopharma Ltd.

Equities

RDHL

US7574682024

Market Closed - Nasdaq
Other stock markets
 21:30:00 28/06/2024 BST 		5-day change 1st Jan Change
0.3707 USD -1.72% Intraday chart for RedHill Biopharma Ltd. +1.20% -74.61%
06-06 RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board CI
05-06 Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board
CI
RedHill Biopharma : Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - Form 6-K
PU
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib
MT
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K
PU
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
PR
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035
CI
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K
PU
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
CI
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
AQ
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
AQ
RedHill Biopharma Ltd. cancelled the transaction announced on March 8, 2023
CI
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection
MT
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K
PU
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
PR
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs
CI
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication
AQ
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences
CI
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
PR
Nasdaq Stocks Under $1 to Watch Now! VTAK, IVP, ONCO, AKTS, RDHL
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RDHL Stock
  4. News RedHill Biopharma Ltd.